News

FDA Grants Orphan Drug Status to AGT-184 for Sanfilippo Type A

AGT-184 has been granted orphan drug designation for the treatment of Sanfilippo syndrome type A by the U.S. Food and Drug Aministration. Sanfilippo syndrome type A is caused by mutations in the gene that provides instructions to make the enzyme N-sulfoglucosamine sulfohydrolase (SGSH). This leads to the accumulation of a complex sugar molecule…

Molecule Called Trehalose Lowered Inflammation and Preserved Vision in Sanfilippo Mouse Model, Study Reports

Treating a mouse model of Sanfilippo with a small molecule, called trehalose, may be a viable therapeutic approach for people with this syndrome, researchers suggest. Their study, “Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency” was published in the journal Autophagy. Autophagy…